Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at Filgrastim Hexal i overensstemmelse med EU’ s krav har en kvalitets -, sikkerheds - og effektprofil, der svarer til Neupogens.
The Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Filgrastim Hexal has been shown to have a comparable quality, safety and efficacy profile to Neupogen.